News

Overall, 42.4% of patients with Huntington disease reported at least 1 psychiatric or cognitive symptom before motor symptoms, with depression being the most common.

The FDA and CDC made the call after 6 reports of the serious blood clot event, which has so far been linked to 1 patient death.

The postdoctoral researcher at Columbia University discussed the use of the DISCO-MS survey and its potential for future research projects.

A group of 15 repurposed agents were identified as the best candidates for activity against the network of 20 related and distinct biochemical pathways that are dysregulated in AD-related dementia.

Ilena George, MD, of Massachusetts General Hospital, discussed a cohort of patients with early DMT prescription and low rates of clinical conversion.

At 6 months, 62% of the 10 kHz spinal cord stimulation treatment group had observed improvement upon investigator-assessed neurological examination, compared to 3% of conventional medical management subjects.

The director and founder of the Sleep Centers of Middle Tennessee discussed the OSAinHome program that his practice has developed.

Patients with highly refractory status epilepticus had greater median hospital length stays as well as greater median hospital costs compared to patients with moderate or low refractory status epilepticus.

The professor of neurology at Johns Hopkins University, and a member of the Curing Coma Campaign’s Scientific Steering Committee spoke to the current limitations of clinical trials in coma.

The consultant in the Department of Neurology at Mayo Clinic discussed the advancements of Parkinson disease knowledge and treatment over the past 2 decades.

Researchers used patient, family, and public engagement to develop a 14-item DMD-QoL questionnaire.

Treatment with fingolimod followed by alemtuzumab led to an increase in spinal relapses as well as increased risk of secondary autoimmunity.

The professor of health science at the Medical University of South Carolina spoke to the dire need for more therapeutic approaches to treat some of the most difficult symptoms of dementia.

Researchers collected data from 457 stroke centers in 70 countries encompassing 6 continents, which included more than 80,000 stroke hospitalizations.

Neurology News Network for the week ending April 10, 2021.

The director of the Institute for Health, Health Care Policy, and Aging Research at Rutgers University discussed the issues that remain with enrolling patients into real-world dementia trials and standardizing measures.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 9, 2021.

The duo from the National Institutes of Health discussed how monitoring and treating paramagnetic rim lesions can improve patient care in multiple sclerosis.

Antisense-mediated reduction of mutant FUS protein previously showed prevention of motor neuron loss in an FUS-ALS mouse model.

The chair of neurology and Olemberg Family Chair of Neurological Disorders at the University of Miami Miller School of Medicine detailed the reasons behind the lack of research on social determinants of health on stroke outcomes.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Bhooma Aravamuthan, MD, DPhil.

Yujie Wang, MD, a neurologist from the University of Washington Medical Center, discussed examining the 1-hour post monitoring period of natalizumab infusion amid the COVID-19 pandemic.

The Gary Sinise Foundation Avalon Network aims to combat TBI and post-traumatic stress in veterans and first responders.

The professor of neurology at Johns Hopkins University, and a member of the Curing Coma Campaign’s Scientific Steering Committee shared her insight into the current management of coma and the need for better prognostication.

Researchers studied associations between CSF neurofilament light, neurogranin, and t-tau with measures of cortical thickness, white matter hyperintensities, and microstructural integrity.

Annualized relapse rate reduction, fatigue, magnetic resonance imaging activity, brain volume loss, and no evidence of disease activity status were all superior in the ponesimod-treated group.

The consultant in the Department of Neurology at Mayo Clinic discussed the mounting number of unmet needs for patients with Parkinson disease.

A majority of patients across all 3 cohorts maintained or improved their motor function shown by changes from baseline in Revised Hammersmith Scale scores.